Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects
- 1 November 2015
- journal article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 495 (1) , 81-86
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
- Ministry of Education (NRF-2013R1A1A2064165)
- Ministry of Science, ICT and Future Planning (NRF-2013R1A1A2062043, NRF-2013R1A2A2A01068858)
This publication has 29 references indexed in Scilit:
- Long acting hyaluronate – exendin 4 conjugate for the treatment of type 2 diabetesBiomaterials, 2010
- Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogsJournal of Controlled Release, 2010
- Preparation and Structural, Biochemical, and Pharmaceutical Characterizations of Bile Acid-Modified Long-Acting Exendin-4 DerivativesJournal of Medicinal Chemistry, 2009
- Incretin-based therapies for type 2 diabetes mellitusNature Reviews Endocrinology, 2009
- Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitusExpert Opinion on Pharmacotherapy, 2008
- Exendin-4 Protects β-Cells From Interleukin-1β–Induced Apoptosis by Interfering With the c-Jun NH2-Terminal Kinase PathwayDiabetes, 2008
- Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on IncretinsEndocrine Reviews, 2008
- Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 DiabetesDiabetes Care, 2007
- Synthesis and Biological Properties of Insulin−Deoxycholic Acid Chemical ConjugatesBioconjugate Chemistry, 2005
- Physicochemical Characteristics of Self-Assembled Nanoparticles Based on Glycol Chitosan Bearing 5β-Cholanic AcidLangmuir, 2003